Antibody Probes to Estrogen Receptor-Alpha Transcript-Specific Upstream Peptides: Alternate ER-Alpha Promoter Use and Breast Cancer Etiology/Outcome
Abstract
Positive Estrogen Receptor alpha (ER) status correlates with a reduced incidence of breast cancer recurrence in the first years after resection of tumors, and predicts a favorable response to adjuvant anti-estrogens. ER-protein in breast tumors increases with patient age. The project develops novel antibody reagents to probe the expression of ER from alternate promoters taking advantage of short peptides encoded in regions of the ER mRNAs that are promoter specific and not shared. We hope that the short transcript specific peptides will act as Biomarkers' of promoter use. In the second year we have developed a new set of polyclonal antisera to one of the short upstream peptides and these are to be tested in immunohistochemical assays for ability to assess promoter use. A set back has been our failure to develop successful monoclonal antibodies, though the primed mice had good immune responses.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2003
- Accession Number
- ADA418096
Entities
People
- Brian T. Pentecost